Hospira profit beats estimates on higher prices, sales

November 6, 2014 7:19 PM

5 0

(Reuters) - Hospira Inc reported a quarterly profit that handily beat analysts' estimates as the company raised prices and sold more of its injectable drugs.

The drugmaker's performance is closely watched by investors for the impact of generic competition on its injectable sedative, Precedex.

Also read: Unilever Has Rejected a $143 Billion Merger Bid From Kraft Heinz

Read more

To category page

Loading...